Executive Roundtable

Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today-how to make that data relevant to payers, regulators and the patient through reliance on real-world evidence in driving better health outcomes.

Pharm Exec convenes a roundtable discussion with several company chief information officers (CIOs) and IMS Health to explore ways to turn the vast reams of data now being generated in the transactional tsunami of modern healthcare into truly meaningful insights for its users.

Experts from industry and academia probe the changing role of the pharmacoepidemiology function as it grapples with the challenges of big data analytics, tightening drug safety requirements, growing post-approval study burdens, and payer expectations around the application of real-world evidence.

In a knowledge industry like biopharma, people are the intangible asset that marks the difference between a status quo or standout performance. Pharm Exec recently convened a panel of industry team leaders and HR specialists at St. Joseph’s University Haub School of Business to parse out some useful best practices in three key areas: talent recruitment and retention; skills training; and workforce diversity.

Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.

From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal.